References
- Doerry, U., & Kent, L. (2003). Prescribing practices of community child and adolescent psychiatrists. Psychiatric Bulletin, 27, 407–410.
- Jureidini, J. N., Doecke, C. J., Mansfield, P. R., Haby, M. M., Menkes, D. B., Tonkin, A. L., et al. (2004). Efficacy and safety of antidepressants for children and adolescents. British Medical Journal, 328, 879 — 883.
- Kjaergard, L., & Als-Nielsen, B. (2002). Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. British Medical Journal, 325, 249. Quoted in P Thomas and P Bracken (2003) Marketing science or the science of marketing? Openmind, 122, 10–11.
- Medawar, C., Herxheimer, A., Bell, A., & Jofre, S. (2002). Paroxetine, Panorama and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance. International Journal of Risk and Safety in Medicine, 15, 161–169.
- Moncrieff, J. (2003). Is psychiatry for sale? Maudsley Discussion Paper. Institute of Psychiatry.
- Moncrieff, J., & Double, D. (2003). Double blind random bluff. Mental Health Today, November 2003.
- Smith, R. (2004). Foregone conclusions. Guardian 14 January 2004.
- Wahlbeck, K., & Adams, C. (1999). Sponsored drug trials show more-favourable outcomes. British Medical Journal, 318, 465.
- Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., Boddington, E., et al. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet, 363, 1341— 1345.